September is Alopecia Areata Awareness Month. Follow blue illuminations across the USA: #LightItUpBlue4AlopeciaAreata Learn More

The quest for new treatment options for alopecia areata

May 26th, 2021

James CassellaBy James V. Cassella, PhD

Drug innovators in the field of alopecia areata have advanced research in an effort to find new ways to treat this challenging autoimmune disorder that affects nearly a million people in the US.

We’re proud to be one of the first to be part of this important medical movement and to count Concert among the biopharmaceutical companies that have taken on the mantle of looking for these innovative approaches. It is encouraging to see multiple new candidates advance into clinical trials for alopecia areata, a once overlooked disorder.

Alopecia areata is an autoimmune disease in which the body’s immune system mistakenly attacks hair follicles, causing patchy or complete loss of hair on the scalp and body as well as other significant physical and psychological symptoms. Alopecia areata affects approximately 1 million Americans at any given time and can be debilitating to their physical and psychological health.

I’m leading the team at Concert Pharmaceuticals that has taken on this challenge. It’s a large mountain to climb, but we are making progress. I’ve been working in science-driven drug discovery and product development companies for over 30 years and I’ve helped to successfully commercialize novel medicines. A key focus and passion of mine over the last six years at Concert and working with the alopecia areata community has been to develop drugs that make a difference for patients.

During my time at Concert, our science and development teams set out to explore a potential new treatment for alopecia areata. Since that time, we have worked with key scientific leaders in the field, physicians, patients and caregivers to guide the development and clinical trial design for our investigational drug candidate, CTP-543.

I am pleased to say that we have successfully advanced CTP-543 into Phase 3 clinical development. We are committed to continuing this effort as we strive to develop a new treatment option for this important medical condition, and we hope that a new treatment could be available to adults with alopecia areata in the early part of 2024.

 

 

Back to Top